Alexion Pharmaceuticals, a unit of AstraZeneca, develops medicines for rare diseases by translating the biology of the complement system into therapeutic treatments. The company has spent over three decades building expertise in rare disease innovation and employs more than 5,000 people across the globe.
Alexion claims to have been the first to harness complement system biology for transformative medicines. The company's research spans translational medicine and biopharmaceutical development, drawing on deep scientific understanding to create therapies for conditions affecting small patient populations.
Operating as part of AstraZeneca's rare disease division, Alexion maintains a collaborative structure that engages researchers, scientists, patient advocates, caregivers, and affected families. The organization combines its scale and resources as an AstraZeneca subsidiary with an entrepreneurial approach to drug development, focusing on following the science and prioritizing patient needs in its work.
